BioVersys Announces Successful AGM Approvals

BioVersys AG, based in Basel, Switzerland, reported the overwhelming approval of all board proposals at its recent Annual General Meeting. The biopharmaceutical company, known for its focus on developing novel antibacterial treatments for serious infections caused by multi-drug resistant bacteria, received unanimous support from its shareholders for all items presented during the meeting.

Key approvals included the acceptance of the 2025 Annual Report and financial statements. The re-election of Dr. Seng Chin Mah and other board members, along with the election of Ms. Simona Skerjanec, were also confirmed. Additionally, compensation packages for the Board of Directors and Executive Committee were approved.

Chairman Dr. Seng Chin Mah expressed gratitude to shareholders for their ongoing trust. With significant progress in Phase 3 trials of BV100 and developments in collaboration with partners, BioVersys remains focused on addressing unmet medical needs.